ES2109516T3 - Derivados de quinoxalinodiona como antagonistas de aminoacidos excitadores. - Google Patents

Derivados de quinoxalinodiona como antagonistas de aminoacidos excitadores.

Info

Publication number
ES2109516T3
ES2109516T3 ES93922849T ES93922849T ES2109516T3 ES 2109516 T3 ES2109516 T3 ES 2109516T3 ES 93922849 T ES93922849 T ES 93922849T ES 93922849 T ES93922849 T ES 93922849T ES 2109516 T3 ES2109516 T3 ES 2109516T3
Authority
ES
Spain
Prior art keywords
hydrogen
alkyl
chr13
chr14
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93922849T
Other languages
English (en)
Inventor
Christopher Franklin Bigge
Thomas Charles Malone
Frank Watjen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2109516T3 publication Critical patent/ES2109516T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UN COMPUESTO QUE TIENE LA FORMULA (I) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN LA QUE R ES HIDROGENO O HIDROXI; R1 ES HIDROGENO, ALQUILO, ARILALQUILO, (CH2)NOH O (CH2)NR7R8; R5 Y R6 SON CADA UNO, INDEPENDIENTEMENTE, HIDROGENO, HALOGENO, NO2, CN, CF3, SO2NR7R8, PO3R9R10, ALQUILO, ALQUENILO, ALQUINILO, (CH2)NCONR7R8, (CH2)NCO2R10, NHCOR11, EN DONDE R7 Y R8 SON CADA UNO, INDEPENDIENTEMENTE, HIDROGENO O ALQUILO O R7 Y R8 JUNTOS FORMAN UN ANILLO DE TRES A SIETE ATOMOS, R9 ES HIDROGENO O ALQUILO, R10 ES HIDROGENO O ALQUILO, R11 ES HIDROGENO O ALQUILO Y N ES UN ENTERO DE CERO A CUATRO; A ES UN ANILLO DE CINCO A SIETE ATOMOS FUSIONADO CON EL ANILLO BENZO EN LAS POSICIONES MARCADAS A Y B Y ESTA FORMADO POR LOS SIGUIENTES RADICALES BIVALENTES: A-NR12-CHR13-CHR14-B, A-CHR13CHR14-NR12-B, A-CHR13-NR12-CHR14-B, A-CHR14-CH2-NR12-CHR13-B, ACHR13-NR12-CH2-CHR14-B, A-CH2-CH2-CHR13-NR12-B, A-NR12-CHR13-CH2-CH2B, A-CH2-CH2-NR12-CH2-CH2-B, A-CH2-CH2-CH2-NR12-CH2-B, A-CH2-NR12CH2-CH2-CH2-B, A-CH2-CH2-CH2-CH2-NR12-B, A-NR12-CH2-CH2-CH2-CH2-B, EN DONDE R12 ES HIDROGENO, CH2CH2OH O ALQUILO Y R13 Y R14 SON CADA UNO, INDEPENDIENTEMENTE, HIDROGENO, CN, CONH2, CH2NH2, CH2OH, ALQUILO, ARILALQUILO, ALQUENILO O CO2R15, EN DONDE R15 ES HIDROGENO O ALQUILO. LOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS DE MAMIFEROS Y RESPONDEN AL BLOQUEO DE RECEPTORES DE ACIDO GLUTAMICO Y ASPARTICO. TAMBIEN SE PRESENTAN LOS PROCESOS PARA LA PREPARACION DE LOS COMPUESTOS Y NUEVOS INTERMEDIOS UTILES EN LOS PROCESOS.
ES93922849T 1992-10-13 1993-10-08 Derivados de quinoxalinodiona como antagonistas de aminoacidos excitadores. Expired - Lifetime ES2109516T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96015792A 1992-10-13 1992-10-13
US3433293A 1993-03-22 1993-03-22
US12477093A 1993-09-24 1993-09-24

Publications (1)

Publication Number Publication Date
ES2109516T3 true ES2109516T3 (es) 1998-01-16

Family

ID=27364627

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93922849T Expired - Lifetime ES2109516T3 (es) 1992-10-13 1993-10-08 Derivados de quinoxalinodiona como antagonistas de aminoacidos excitadores.

Country Status (10)

Country Link
US (1) US6703391B2 (es)
EP (1) EP0664807B1 (es)
JP (1) JPH08502483A (es)
AT (1) ATE157977T1 (es)
AU (1) AU680632B2 (es)
DE (1) DE69313866T2 (es)
DK (1) DK0664807T3 (es)
ES (1) ES2109516T3 (es)
GR (1) GR3025257T3 (es)
WO (1) WO1994009000A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843945A (en) * 1993-05-13 1998-12-01 Neurosearch A/S AMPA antagonists and a method of treatment
WO1994026747A1 (en) * 1993-05-13 1994-11-24 Neurosearch A/S Ampa antagonists and a method of treatment therewith
EP0705834A1 (de) * 1994-07-27 1996-04-10 Ciba-Geigy Ag Azaaliphatisch Überbrückte Chinoxalin-2,3-dione
EP0705835A1 (de) * 1994-09-01 1996-04-10 Ciba-Geigy Ag Oxa- oder thiaaliphatisch überbrückte Chinoxalin-2,3-dione
EE03772B1 (et) * 1994-09-14 2002-06-17 Neurosearch A/S Kondenseeritud indooli ja kinoksaliini derivaadid, nende valmistamine ja kasutamine
AU687255B2 (en) * 1994-09-14 1998-02-19 Neurosearch A/S Indole-2,3-dione-3-oxime derivatives, their preparation and use
AU4423496A (en) * 1995-03-14 1996-10-02 Warner-Lambert Company Novel glutamate (ampa/kainate) receptor antagonists: n-substituted fused azacycloalkylquinoxalinediones
AU3571997A (en) * 1996-08-01 1998-02-25 Warner-Lambert Company Novel glutamate receptor antagonists: fused cycloalkyl quinoxalinediones
WO2002014277A1 (en) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
WO2002014276A1 (en) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Benzoylaminoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
DE10121215A1 (de) 2001-04-30 2002-10-31 Merck Patent Gmbh Dihydro-imidazo[4,5-e]indol- und 7H-Pyrrolo[3,2-f]chinoxalin Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
WO2007059608A1 (en) 2005-11-23 2007-05-31 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
CA2652307A1 (en) * 2006-04-10 2007-10-18 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
WO2012014910A1 (ja) * 2010-07-29 2012-02-02 日本ケミファ株式会社 Ｐ２ｘ４受容体拮抗剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK146787A (da) * 1987-03-23 1988-09-24 Ferrosan Heterocykliske forbindelser, deres fremstilling og anvendelse
DK160941C (da) 1988-06-28 1991-10-21 Novo Nordisk As Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar
DK716188D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
DK101290D0 (da) 1990-04-24 1990-04-24 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
HU221425B (en) 1990-11-06 2002-10-28 Yamanouchi Pharma Co Ltd Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
MX9204914A (es) 1991-08-28 1993-07-01 Frank Watjen Nuevos derivados de isatinoxima, metodo para su preparacion y composicion farmaceutica que los comprende.
AU4423496A (en) * 1995-03-14 1996-10-02 Warner-Lambert Company Novel glutamate (ampa/kainate) receptor antagonists: n-substituted fused azacycloalkylquinoxalinediones

Also Published As

Publication number Publication date
ATE157977T1 (de) 1997-09-15
AU680632B2 (en) 1997-08-07
EP0664807A1 (en) 1995-08-02
AU5171593A (en) 1994-05-09
DE69313866D1 (de) 1997-10-16
US6703391B2 (en) 2004-03-09
EP0664807B1 (en) 1997-09-10
WO1994009000A1 (en) 1994-04-28
JPH08502483A (ja) 1996-03-19
DE69313866T2 (de) 1998-03-05
GR3025257T3 (en) 1998-02-27
DK0664807T3 (da) 1998-04-27
US20030114422A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
ES2109516T3 (es) Derivados de quinoxalinodiona como antagonistas de aminoacidos excitadores.
PE46899A1 (es) Derivados de n-fenil-sulfonamida
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
ES2160596T3 (es) Derivados de quinuclidina como antagonistas de la sustancia p.
SE8900039L (sv) Isokinolinderivat, deras framstaellning och deras anvaendning
AR241414A1 (es) Procedimiento para la preparacion de derivados de 2,2'-iminobisetanol y obtencion de intermediarios.
YU159291A (sh) Analozi azota sa kondenzovanim prstenom koji sadrže nearomatske heterocikle
EA199900531A1 (ru) Хинолиновые и хиназолиновые соединения, применяемые в терапии, особенно при лечении доброкачественной гиперплазии простаты
MX9703286A (es) Inhibidores de la proliferacion celular en musculo liso.
ES2129483T3 (es) Derivados de indol-7-carboxamida como analgesicos.
ID16001A (id) Turunan 3,4-dihidroisokuinolin dan penggunaan leburan dihidropiridina sebagai senyawa farmasi
ES2071479T3 (es) Derivados de indano.
ES515904A0 (es) "procedimiento para preparar nuevas triazoloquinazolonas".
ES2182509T3 (es) Derivados de n-ariloxietilamina para el tratamiento de la depresion.
ES544828A0 (es) Procedimiento para preparar nuevos compuestos de 3-(aminoal-quilaminocarbonilmetoxi)-5-fenilpirazol
FI852672L (fi) Ringfusionerade pyrazolo(3,4-d)-pyridin -3-onderivat.
ES2038532B1 (es) Procedimiento de preparacion de nuevos derivados de 2-piperacinilbecimidazol.
CO4950554A1 (es) Derivados de 1,3-dihidro o 3,4-dihidroisoquinolin-benzamida
AR009665A1 (es) Compuestos derivados de pirrolidinamida sustituidos con heterociclos, utiles como antagonistas de receptores de taquiquininas, composiciones farmaceuticas que incluyen dichos compuestos, usos en la preparacion de composiciones farmaceuticas para tratamiento de enfermedades y procedimiento de preprac
DK52383A (da) Fremgangsmaade til fremstilling af carbacyklinderivater
NO900646L (no) Fremgangsmaate for fremstilling av calsiumantagonister.
ATE31924T1 (de) Phenethyl-1-alpha-phenyl-piperidin-3-propannitr l-derivate, ihre herstellung und therapeutische verwendung.
DE3882589D1 (de) 4-substituierte 10-cyanmethylenpyrrolo(4,3-e)-benzo-azepine.
AR053437A1 (es) Procesos y compuestos para la preparacion de derivados de naftilindol sustituidos
FI933119L (fi) 4- ja 6-substituoidut 1,2,3,3a,8,8a-heksahydro-1,3a,8-trimetyylipyrrolo/2,3-b/indolijohdannaiset

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 664807

Country of ref document: ES